Please don't hesitate to contact us if you have any questions or other inquiries.

Nordic Bioscience's landmark collaboration study on PRO-C6 in NEJM Evidence has received two editorials.

Nordic Bioscience announced in its recent press release that we have published a study in NEJM Evidence in collaboration with Bristol Myers Squibb and the University of Pennsylvania. The article demonstrates the clinical utility of endotrophin, a pro-fibrotic molecule measured by the biomarker PRO-C6 in the context of heart failure.

The first editorial, written by Jonathan W. Cunningham, M.D., M.P.H., and Marc A. Pfeffer, M.D., Ph.D., contrasts the results of the study with a 2007 article that proposed three criteria for evaluating new cardiovascular biomarkers. The first criterion is the provision of clinically relevant information. The second is whether the biomarker adds new information to current testing methods. And the third is whether the measurement can change clinical practice decisions. The authors assess that,

1) "Endotrophin measurements were reproducible and stable over time", noting that further validation is needed;

2) "The recently published HFpEF-specific score that combines clinical and biomarker data provides more appropriate competition", adding that the extent of improvement in risk prediction is uncertain at this time; and

3) "Identifying patients with HFpEF who are at greatest risk for death is only marginally important in routine practice", implying that the authors believe it is less important to segregate patients who are more likely to die, based on current treatment methods.

The second editorial, authored by Thomas A. Trikalinos, M.D., Ph.D., assesses that the study shows a strong association with all-cause mortality and adverse outcome in patients with heart failure with preserved ejection fraction (HFpEF). As per Trikalinos, "at a minimum, their observation is new knowledge that may advance our understanding of the pathophysiology of HFpEF. It also indicates that endotrophin-based risk prediction has utility for patients, the health system, and designing future research."

Nordic Bioscience and our partners are pleased that the endotrophin publication in NEJM Evidence has generated such additional interest, and we look forward to receiving further expert opinion on the clinical utility of PRO-C6.


Click here if you would like to learn more about endotrophin and PRO-C6

Please don't hesitate to contact us if you have any questions or other inquiries.

Are you interested in learning more about Nordic Bioscience?
Enter your information in the form and a representative will contact you shortly.

By submitting this form you agree to our terms and conditions.